½ÃÀ庸°í¼­
»óǰÄÚµå
1586025

Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå : ¾àÈ¿±ºº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åëä³Îº° - ¼¼°è Àü¸Á(2025-2030³â)

Calcium Channel Blockers Market by Drug Class (Benzodiazepine, Dihydropyridine, Phenylalkylamine), End User (Homecare, Hospitals, Specialty Clinics), Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 188 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀåÀº 2023³â¿¡ 135¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 142¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.23%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 206¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Ä®½· ä³Î Â÷´ÜÁ¦(CCBs)´Â Ä®½· ÀÌ¿ÂÀÌ ½ÉÀå°ú µ¿¸ÆÀÇ Ç÷°ü ÆòȰ±Ù ¼¼Æ÷·Î µé¾î°¡´Â °ÍÀ» ¾ïÁ¦ÇÏ¿© ÁÖ·Î °íÇ÷¾Ð, Çù½ÉÁõ ¹× ƯÁ¤ ½ÉÀå ºÎÁ¤¸ÆÀ» °ü¸®ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¾à¹°ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¾ïÁ¦ ÀÛ¿ëÀº Ç÷°üÀÇ À̿ϰú È®ÀåÀ» °¡Á®¿Í ½ÉÇ÷°ü°è Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. µµ½ÃÈ­, ÁÂ½Ä »ýȰ½À°ü, °í·ÉÈ­·Î ÀÎÇØ ½ÉÇ÷°ü ÁúȯÀÇ Àü ¼¼°è À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó CCBÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, CCBÀÇ ¿ëµµ´Â °íÇ÷¾Ð °ü¸®¸¦ À§ÇÑ ÀǾàǰ ó¹æºÎÅÍ ÁöÁÖ¸·ÇÏ ÃâÇ÷ ÈÄ ³úÇ÷°ü °æ·Ã Ä¡·á¿¡ »ç¿ëµÇ´Â Á¦Á¦±îÁö ´Ù¾çÇÕ´Ï´Ù. ÃÖÁ¾ »ç¿ëó´Â º´¿ø, Áø·á¼Ò, ¼Ò¸Å ¾à±¹ µî ´Ù¾çÇÑ È¯ÀÚÃþÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¹üÀ§°¡ ³Ð´Ù. ½ÃÀå ¼ºÀåÀº ½ÉÇ÷°ü °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¾à¹° Á¦Á¦ ±â¼úÀÇ ¹ßÀü, ÆíµÎÅë ¹× ·¹À̳ë Çö»ó°ú °°Àº ´Ù¸¥ Áúº´¿¡ ´ëÇÑ Àû¿ë È®´ë µîÀÇ ¿äÀο¡ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ´Â ºÎÀÛ¿ëÀÌ Àû°í, »ýü ÀÌ¿ë·üÀÌ ³ôÀ¸¸ç, ´Ù¸¥ ½ÉÇ÷°ü Ä¡·áÁ¦¿ÍÀÇ È£È¯¼ºÀÌ ³ôÀº CCB °³¹ß¿¡¼­ ãÀ» ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ÀáÀçÀûÀÎ ºÎÀÛ¿ë, ±î´Ù·Î¿î ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, Á¦³×¸¯ ÀǾàǰÀÇ Àαâ Áõ°¡ µîÀÇ ¹®Á¦·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀÌ Á¦Çѵǰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ȯÀÚ ¼øÀÀµµ ¹× °á°ú¸¦ °³¼±Çϱâ À§ÇÑ µðÁöÅÐ Çコ ±â¼ú ÅëÇÕ°ú °°Àº ºÐ¾ß¿¡¼­ Çõ½ÅÀÇ ¿©Áö°¡ ¹«¸£ÀͰí ÀÖ½À´Ï´Ù. CCB ½ÃÀåÀº ²÷ÀÓ¾ø´Â °æÀï°ú Çõ½ÅÀÇ ¾Ð·ÂÀ¸·Î ÀÎÇØ ¿ªµ¿ÀûÀÎ ¼º°ÝÀ» ¶ì°í ÀÖÀ¸¸ç, È¿´É°ú ȯÀÚ °æÇèÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛÀ» ޱ¸ÇÏ´Â ¿¬±¸¿¡ ÅõÀÚÇÏ´Â ±â¾÷ÀÌ ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå Á¡À¯À²À» È®´ëÇϰíÀÚ ÇÏ´Â ±â¾÷Àº Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®, Àü·«Àû ÆÄÆ®³Ê½Ê, °­·ÂÇÑ R&D ÅõÀÚ¸¦ ÅëÇØ ºü¸£°Ô ÁøÈ­ÇÏ´Â ½ÃÀå¿¡¼­ ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 135¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 142¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 206¾ï 4,000¸¸ ´Þ·¯
CAGR(%) 6.23%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ÀúÇ÷¾Ð ȯÀÚ Áõ°¡
    • Áúº´ÀÇ Á¶±â Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ °ü½É
    • ÀúÇ÷¾Ð Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¦Ç° ¸®ÄÝ, ¿øÀÚÀç °¡°Ý º¯µ¿
  • ½ÃÀå ±âȸ
    • ½Å¼¼´ë Ä®½· ä³Î Â÷´ÜÁ¦ ¼Ò°³
    • Ä®½· ä³Î Â÷´ÜÁ¦ È¿°ú °ËÁõÀ» À§ÇÑ ÀÓ»ó½ÃÇè
  • ½ÃÀå °úÁ¦
    • Ä®½· ä³Î Â÷´ÜÁ¦¿Í °ü·ÃµÈ ºÎÀÛ¿ë

Portre's Five Forces: Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ ±×¸®´Ù.

Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

  • Benzodiazepine
  • Dihydropyridine
  • Phenylalkylamine

Á¦7Àå Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ȨÄɾî
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦8Àå Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ä®½· ä³Î Â÷´ÜÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Apotex Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals U.S. Inc.
  • Hikma Pharmaceuticals PLC
  • INTAS PHARMACEUTICALS LTD.
  • Kyowa Kirin Co., Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OTSUKA PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
LSH 24.11.13

The Calcium Channel Blockers Market was valued at USD 13.52 billion in 2023, expected to reach USD 14.25 billion in 2024, and is projected to grow at a CAGR of 6.23%, to USD 20.64 billion by 2030.

Calcium Channel Blockers (CCBs) are a class of medications used primarily to manage hypertension, angina, and certain heart arrhythmias by inhibiting calcium ions from entering cardiac and arterial vascular smooth muscle cells. This blockade results in relaxation and dilation of blood vessels, making them essential in cardiovascular treatment protocols. The scope of CCBs extends beyond traditional uses, as their necessity increases with the rising global prevalence of cardiovascular diseases due to urbanization, sedentary lifestyles, and aging populations. The application niche for CCBs spans from pharmaceutical prescriptions for high blood pressure management to formulations used in treating cerebral vasospasm post-subarachnoid hemorrhage. The end-use scope includes hospitals, clinics, and retail pharmacies, making them accessible to a broad patient demographic. Market growth is significantly influenced by factors such as increasing awareness of cardiovascular health, advancements in drug formulation technologies, and expanded applications in other diseases like migraines and Raynaud's phenomenon. An emerging opportunity lies in the development of CCBs with fewer side effects, improved bioavailability, and compatibility with other cardiovascular drugs. However, market growth is curtailed by challenges such as potential side effects, strict regulatory approvals, and the rising popularity of generic alternatives. The scope for innovation is ripe in areas such as personalized medicine and the integration of digital health technologies to enhance patient adherence and outcomes. Companies stand to gain by investing in research exploring novel drug delivery systems that enhance efficacy and patient experience. The CCB market exhibits a dynamic nature characterized by constant competition and innovation pressure. Players seeking substantial market share should emphasize comprehensive market analyses, strategic partnerships, and robust R&D investments to stay ahead in the rapidly evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 13.52 billion
Estimated Year [2024] USD 14.25 billion
Forecast Year [2030] USD 20.64 billion
CAGR (%) 6.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Calcium Channel Blockers Market

The Calcium Channel Blockers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of low blood pressure worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Increasing awareness regarding low blood pressure treatments
  • Market Restraints
    • Product recall and volatility in raw material cost
  • Market Opportunities
    • Introduction of new generation calcium channel blockers
    • Clinical trials to test the efficacy of calcium channel blockers
  • Market Challenges
    • Adverse effects associated with calcium channel blockers

Porter's Five Forces: A Strategic Tool for Navigating the Calcium Channel Blockers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Calcium Channel Blockers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Calcium Channel Blockers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Calcium Channel Blockers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Calcium Channel Blockers Market

A detailed market share analysis in the Calcium Channel Blockers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Calcium Channel Blockers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Calcium Channel Blockers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Calcium Channel Blockers Market

A strategic analysis of the Calcium Channel Blockers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Calcium Channel Blockers Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cadila Pharmaceuticals Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals U.S. Inc., Hikma Pharmaceuticals PLC, INTAS PHARMACEUTICALS LTD., Kyowa Kirin Co., Ltd., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, OTSUKA PHARMACEUTICAL CO., LTD., Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Calcium Channel Blockers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Benzodiazepine, Dihydropyridine, and Phenylalkylamine.
  • Based on End User, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of low blood pressure worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Increasing awareness regarding low blood pressure treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall and volatility in raw material cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new generation calcium channel blockers
      • 5.1.3.2. Clinical trials to test the efficacy of calcium channel blockers
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with calcium channel blockers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Calcium Channel Blockers Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Benzodiazepine
  • 6.3. Dihydropyridine
  • 6.4. Phenylalkylamine

7. Calcium Channel Blockers Market, by End User

  • 7.1. Introduction
  • 7.2. Homecare
  • 7.3. Hospitals
  • 7.4. Specialty Clinics

8. Calcium Channel Blockers Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Calcium Channel Blockers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Calcium Channel Blockers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Calcium Channel Blockers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Bausch Health Companies Inc.
  • 5. Bayer AG
  • 6. Boehringer Ingelheim International GmbH
  • 7. Bristol Myers Squibb Company
  • 8. Cadila Pharmaceuticals Limited
  • 9. Daiichi Sankyo Company, Limited
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Glenmark Pharmaceuticals U.S. Inc.
  • 12. Hikma Pharmaceuticals PLC
  • 13. INTAS PHARMACEUTICALS LTD.
  • 14. Kyowa Kirin Co., Ltd.
  • 15. Lupin Pharmaceuticals, Inc.
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. OTSUKA PHARMACEUTICAL CO., LTD.
  • 19. Pfizer Inc.
  • 20. Sanofi S.A.
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦